Progress in ligand design for monolayer-protected nanoparticles for nanobio interfaces

• Published in: Biointerphases Vol. 13; no. 6; p. 06D502
• Main Authors: Manning, Matthew D, Kwansa, Albert L, Oweida, Thomas, Peerless, James S, Singh, Abhishek, Yingling, Yaroslava G
• Format: Journal Article
• Language: English
• Published: United States 01.12.2018
• Subjects: Drug Carriers - chemistry; Humans; Nanomedicine - economics; Nanomedicine - methods; Nanomedicine - trends; Nanoparticles - chemistry; Surface Properties; Technology, Pharmaceutical - economics; Technology, Pharmaceutical - methods; Technology, Pharmaceutical - trends
• ISSN: 1934-8630; 1559-4106
• DOI: 10.1116/1.5044381

Ligand-functionalized inorganic nanoparticles, also known as monolayer-protected nanoparticles, offer great potential as vehicles for delivery of drugs, genes, and other therapeutics. These nanoparticles offer highly customizable chemistries independent of the size, shape, and functionality imparted by the inorganic core. Their success as drug delivery agents depends on their interaction with three major classes of biomolecules: nucleic acids, proteins, and membranes. Here, the authors discuss recent advances and open questions in the field of nanoparticle ligand design for nanomedicine, with a focus on atomic-scale interactions with biomolecules. While the importance of charge and hydrophobicity of ligands for biocompatibility and cell internalization has been demonstrated, ligand length, flexibility, branchedness, and other properties also influence the properties of nanoparticles. However, a comprehensive understanding of ligand design principles lies in the cost associated with synthesizing and characterizing diverse ligand chemistries and the ability to carefully assess the structural integrity of biomolecules upon interactions with nanoparticles.